Back to search

Article

Tirzepatide but not Semaglutide Ameliorates Hepatic Steatosis and Inflammatory Infiltration in a Mouse Model of MASLD via Inhibition of the CCL2/CCR2-PI3K-Akt Pathway

2025-10-07

Abstract excerpt

<title>Abstract</title> <p> <bold>Background/Objectives</bold> Metabolism-associated steatohepatitis (MASLD) is a common multisystem chronic progressive liver disease whose prevalence has been steadily increasing in recent years. Tirzepatide is a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Studies have shown that Tirzepatide can also reduce l...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
327fb369-33dd-5198-aa87-1545b67a8fac
DOI
10.21203/rs.3.rs-7562588/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Tirzepatide but not Semaglutide Ameliorates Hepatic Steatosis and Inflammatory Infiltration in a Mouse Model of MASLD via Inhibition of the CCL2/CCR2-PI3K-Akt PathwayDOI 10.21203/rs.3.rs-7562588/v1
<i>Patolakaturohiniyadi Kashayam</i> , exerts anti-steatotic and anti-obesogenic effects via coordinated regulation of lipid metabolism, inflammation, and incretin signallingSemantic proximity
Modulation of metabolic, inflammatory, fibrotic and cell death pathways by Resmetirom in metabolic dysfunction-associated steatohepatitis (MASH): A transcriptomic profiling studySemantic proximity
Differences Between Therapeutic Mechanisms of Resmetirom and Semaglutide Against MASH in Western diet-fed MC4R Knockout MiceSemantic proximity
Regulation of fatty acid oxidation by liraglutide via SIRT1 in hepatocytes: A mechanistic studySemantic proximity
PPARα-ERRα crosstalk mitigates metabolic dysfunction-associated steatotic liver disease progressionSemantic proximity
Therapeutic Mechanisms of Medicine and Food Homology Formula Xiao-Ke-Yin on Glucolipid Metabolic Dysfunction Revealed by Transcriptomics, Metabolomics and Microbiomics in miceSemantic proximity
Explore of potential targets and mechanisms of hesperetin in treating metabolic dysfunction-associated steatosis liver disease via network pharmacology and in vitro experimentsSemantic proximity
Combined Semaglutide and Exercise Ameliorate HFpEF-Associated MASH: Multi-Omics InsightsSemantic proximity
A new dietary rat model fully recapitulates metabolic dysfunction-associated steatotic liver disease pathophysiology and mimics human disease with advanced liver fibrosis and portal hypertensionSemantic proximity
Efficacy and Safety of GLP-1 Receptor Agonists in Patients with MASLD: A Systematic Review and Meta-analysis of Randomized Clinical TrialsSemantic proximity
Hepatic loss of AATF attenuates MASH by suppressing AKT–mTORC1 signaling and reprogramming lipid metabolismSemantic proximity
Fenofibrate Alleviates Insulin Resistance and Hepatic Steatosis via Modulation of let-7/ SERCA2b&nbsp;AxisSemantic proximity
Select a neighboring publication to make it the new centre.